


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1 to 7. (Canceled)

8. (Currently Amended) A pharmaceutical composition comprising a compound of Formula I



Wherein

m is 0, 1, 2 or 3;


n is 0 or 1;

–A–B–C–D– is selected from the group consisting of:

- (1) –CH₂–CH₂–CH₂–O–,
- (2) –CH₂–CH₂–C(O)–O–,
- (3) –CH=CH–C(O)–O–,
- (4) –O–CH₂–CH₂–CH₂–,
- (5) –O–C(O)–CH₂–CH₂–,
- (6) –HC=CH–CH₂–O–,
- (7) –CH₂–HC=CH–O–,
- (8) –CH₂–CH₂–C(O)–NH–,
- (9) –CH₂–NH–CH₂–CH₂–,
- (10) –CH₂–NH–C(O)–O–,
- (11) –NH–C(O)–NH–C(O)–,
- (12) –C(O)–NH–C(O)–NH–,

- (13) $\text{-NH-C(O)-NH-CH}_2\text{-}$,
(14) $\text{-NH-C(O)-NH-C(=S)-}$,
(15) $\text{-O-CH}_2\text{-CH}_2\text{-O-}$ and
(16) $\text{-S-CH}_2\text{-CH}_2\text{-S-}$;

provided that when the atoms at positions B and C of -A-B-C-D- are both carbon atoms, said atoms may be joined together to form a ring selected from



R^1 is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- (a) halo,
(b) OCH_3 ,
(c) CH_3 , and
(d) CN ;

R^2 and R^3 are each individually hydrogen or methyl; and

each R^4 is independently selected from the group consisting of

- (1) -OH ,
(2) $\text{-C}_{1-6}\text{alkyl}$ optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH , amino, methylamino, di-methylamino, $=\text{S}$, and halo,
(3) $\text{C}_{2-6}\text{alkenyl}$ optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and $\text{-C(O)-O- C}_{1-2}\text{alkyl}$,
(4) $\text{C}_{2-6}\text{alkynyl}$ optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,
(5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, $\text{C}_{1-2}\text{alkyl}$, -COOH , -C(O)-O-CH_3 and halo,

(6) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,

(7) -CO₂H,

(8) -CO₂C₁₋₃alkyl,

(9) -OC₁₋₃alkyl,

(10) -SO₂-C₁₋₃alkyl,

(11) -SO₂-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo

(12) -C₁₋₂alkyl-O-C₁₋₂alkyl,

(13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,

(14) -C₁₋₂alkyl-O-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,


(15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,

(16) 2-(1,3-dioxan)ethyl,

(17) -C₁₋₂alkyl-C(O)-NH-phenyl and

(18) -C₁₋₂alkyl-C(O)-NHN;

in combination with a pharmaceutically acceptable carrier,
with the proviso that the compound of Formula I is other than



9. (Previously Presented) The pharmaceutical composition according to claim 8

wherein

Each R⁴ is independently selected from the group consisting of

(1) -OH,

(2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected

independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, thio, and halo,

(3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,

(4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,

(5) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,

(6) -SO₂-C₁₋₃alkyl, and

(7) -C₁₋₂alkyl-OC₁₋₂alkyl.

10. (Previously Presented) The pharmaceutical composition according to claim 9 wherein

-A-B-C-D- is selected from the group consisting of:

(1) -CH₂-CH₂-CH₂-O-,

(2) -CH=CH-CH₂-O-,

(3) -CH₂-CH=CH-O-,

(4) -O-CH₂-CH₂-CH₂-,

(5) -O-CH₂-CH₂-O-,


(6) -S-CH₂-CH₂-S-,

(7) -CH₂-NH-CH₂-CH₂-, and

(8) -CH₂-NH-C(O)-O-;

R¹ is phenyl optionally mono or di- substituted with halo.

11. (Previously Presented) A compound of Formula II



II

Wherein

m is 0, 1 or 2;

n is 0 or 1;

X and Y are each independently selected from CH₂, S and O;

R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- (a) halo,
- (b) OCH₃,
- (c) CH₃, and
- (d) CN;

R² and R³ are each individually hydrogen or methyl; and

each R⁴ is independently selected from the group consisting of

- (1) -OH,
- (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, =S, and halo,
- (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,
- (4) C₂₋₆alkynyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,
- (5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
- (6) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (7) -CO₂H,
- (8) -CO₂C₁₋₃alkyl,
- (9) -OC₁₋₃alkyl,
- (10) -SO₂-C₁₋₃alkyl,
- (11) -SO₂-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂ alkyl and halo
- (12) -C₁₋₂alkyl-O-C₁₋₂alkyl,
- (13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,
- (14) -C₁₋₂alkyl-O-phenyl optionally substituted with with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,
- (16) 2-(1,3-dioxan)ethyl,
- (17) -C₁₋₂alkyl-C(O)-NH-phenyl and


(18) $-C_1-2\text{alkyl}-C(O)-NHN$.


12. (Previously Presented) A compound according to claim 11 wherein each R^4 is independently selected from the group consisting of $-C_1-6\text{alkyl}$ or hydrogen.


13. (Previously Presented) A compound according to claim 11 wherein X and Y are both O or are both S or X is O and Y is CH_2 ; and R^1 is phenyl optionally mono or di- substituted with halo.


14. (Previously Presented) A compound selected from one of the following groups:


i)



















ii)



K	R
---	---

1	Vinyl
1	Phenyl
1	4-fluorophenyl
2	Benzyl
2	Vinyl
2	Ethyl


iii)




k	D	A	C	Ra	Rb
1	O	CH ₂	CH ₂	propyl	Propyl
1	O	CH ₂	CHOH	propyl	Propyl
1	O	CH ₂	CH ₂	allyl	Allyl
1	O	CH ₂	CHOH	allyl	Allyl
1	O	CH ₂	CH ₂	methyl	Methyl
1	O	CH ₂	CHOH	methyl	Methyl
1	O	CH ₂	C(O)	methyl	Methyl
1	O	CH ₂	CH ₂	H	H
1	O	CH ₂	CHOH	H	H
2	CH ₂	O	CH ₂	ethyl	H
2	CH ₂	O	CH ₂	H	Ethyl
2	CH ₂	O	CH ₂	H	Phenyl
2	O	CH ₂	CH(allyl)	allyl	Allyl
2	O	CH ₂	CH ₂	methyl	Methyl


2	O	CH ₂	CH ₂	benzyl	Benzyl
2	O	CH ₂	CH ₂	allyl	Allyl
2	O	CH ₂	CHOH	methyl	Methyl
2	O	CH ₂	CHOH	allyl	Allyl
2	O	CH ₂	CH(allyl)	H	H
2	O	CH ₂	C(O)	methyl	Methyl
2	O	CH ₂	C(O)	allyl	Allyl


iv)








Page 17



















v)




k	R
1	phenyl
2	ethyl
2	phenyl



vi)



Ra
Methyl
Allyl
Isopropyl
2-methoxyethyl
CH ₂ CO ₂ Et
2-(1,3-dioxan)ethyl


vii)





C1	D1	A1	B1
C(O)	NCH ₃	C(O)	NH
NCH ₂ Ph	C(O)	NCH ₃	C(O)
NCH ₃	C(O)	NCH ₃	C(O)
NCH ₂ CH=C H ₂	C(O)	NCH ₃	C(O)
C(O)	NCH ₃	C(O)	NCH ₂ Ph
C(O)	NCH ₃	C(O)	NCH ₃
C(O)	NCH ₃	C(O)	NCH ₂ CH=C H ₂
C(O)	NCH ₃	C(O)	NH
N(CH ₂) ₂ CO ₂ H	C(O)	NCH ₂ Ph	C(O)
NH	C(O)	N(CH ₂) ₂ CO ₂ H	C(O)
NH	C(O)	N(CH ₂) ₂ 	C(O)
C(O)	NCH ₃	C(O)	N(CH ₂) ₂ CO ₂ H
C(O)	NCH ₃	C(O)	N(CH ₂) ₂ 
NCH ₂ CH=C H ₂	C(O)	NCH ₂ CH=C H ₂	C(O)
NCH ₂ Ph	C(O)	NCH ₂ Ph	C(O)
NH	C(S)	NCH ₂ Ph	C(O)


NH	C(S)	NH	C(O)
NH	C(S)	NCH ₂ CH=C H ₂	C(O)
NH	C(S)	NCH ₃	C(O)
NH	CH ₂	NCH ₂ Ph	C(O)
NH	CH ₂	NH	C(O)
C(O)	NCH ₃	CH ₂	NCH ₃
NH	CH ₂	NCH ₃	C(O)


and viii)










































































or a pharmaceutically acceptable salt of any of the foregoing compounds.

15 to 21. (Canceled)

22. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 11 in combination with a pharmaceutically acceptable carrier.

23 to 29. (Canceled)